- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Rythmol Rythmol SR
Synonyms :
propafenone
Class :
antiarrhythmics
Dosage Forms & Strengths
Tablet
150mg
225mg
300mg
Capsule-ER
225mg
325mg
425mg
150 mg orally every 8hours; may increase up to 225 mg every 8 hours after 3-4 days
Do not exceed 300 mg every 8 hours
Safety and efficacy not established
Refer adult dosing
propafenone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propafenone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propafenone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propafenone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propafenone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may increase the QT-prolonging effect and enhance the risk of bradycardia, hypokalemia
CYP3A strong enhancers of the small intestine may reduce the bioavailability of propafenone
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the QTc prolonging effect
It may enhance the risk of adverse reactions when combined with sodium
may enhance the adverse/toxic effect of lacosamide
Frequency Defined
>10%
Visual disturbances
Dizziness
1-10%
Arrhythmias
Edema
Asthenia
Palpitations
Fatigue
Tremors
Fever
Tachycardia
Sinus pause/arrest
Vomiting
Diarrhea
Dyspepsia
Anorexia
Rash
Diplopia
Hypoesthesia
Paresthesia
Paresis
Ataxia
Pregnancy warnings:
Pregnancy category: N/A
Breastfeeding warnings:
The release of the drug into the human breastmilk is known
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: propafenone
Pronunciation: proe-PAF-e-none
Why do we use propafenone?
propafenone belongs to the class antiarrhythmics used to treat atrial Fibrillation, atrial flutter, Paroxysmal Supraventricular Tachycardia, and ventricular Tachycardia